Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Winer

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 2022
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]G Curigliano, V Mueller, V Borges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJ S Abramson, T Feldman, A R Kroll-Desrosiers, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trialsM Martín, S Loibl, T Hyslop, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)F Cardoso, A Costa, L Norton, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramF Cardoso, J M S Bartlett, L Slaets, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)F Cardoso, A Costa, E Senkus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2014
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†F Cardoso, A Costa, L Norton, et al.
Breast (Edinburgh, Scotland)|December 9, 2016
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)F Cardoso, A Costa, E Senkus, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 2022
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]G Curigliano, V Mueller, V Borges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJ S Abramson, T Feldman, A R Kroll-Desrosiers, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trialsM Martín, S Loibl, T Hyslop, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)F Cardoso, A Costa, L Norton, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramF Cardoso, J M S Bartlett, L Slaets, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)F Cardoso, A Costa, E Senkus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2014
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†F Cardoso, A Costa, L Norton, et al.
Breast (Edinburgh, Scotland)|December 9, 2016
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)F Cardoso, A Costa, E Senkus, et al.
Pageof 7